Literature DB >> 28314734

FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia.

Chi Keung Cheng1, Angela Z Wang1, Terry H Y Wong1, Thomas S K Wan1, Joyce S Cheung1, Radha Raghupathy2, Natalie P H Chan1, Margaret H L Ng1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28314734     DOI： 10.1182/blood-2017-02-767707

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

Review 1.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Authors:  Miguel A Sanz; Pierre Fenaux; Martin S Tallman; Elihu H Estey; Bob Löwenberg; Tomoki Naoe; Eva Lengfelder; Hartmut Döhner; Alan K Burnett; Sai-Juan Chen; Vikram Mathews; Harry Iland; Eduardo Rego; Hagop Kantarjian; Lionel Adès; Giuseppe Avvisati; Pau Montesinos; Uwe Platzbecker; Farhad Ravandi; Nigel H Russell; Francesco Lo-Coco
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

2.  Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions.

Authors:  Lijun Wen; Yang Xu; Li Yao; Nana Wang; Qinrong Wang; Tianhui Liu; Jinlan Pan; Jiannong Cen; Huifeng Zhou; Miao Miao; Yang W Shao; Xiaonan Wang; Xiaoxia Wang; Changgeng Ruan; Depei Wu; Suning Chen
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

3.  Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes.

Authors:  Michaela Dostalova Merkerova; Jiri Klema; David Kundrat; Katarina Szikszai; Zdenek Krejcik; Andrea Hrustincova; Iva Trsova; Anh Vu LE; Jaroslav Cermak; Anna Jonasova; Monika Belickova
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

Review 4.  Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Authors:  Xiang Zhang; Jiewen Sun; Wenjuan Yu; Jie Jin
Journal:  Biomark Res       Date:  2021-05-06

5.  MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B.

Authors:  Yimin Chen; Shuyi Chen; Jielun Lu; Danyun Yuan; Lang He; Pengfei Qin; Huo Tan; Lihua Xu
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

6.  Arsenic trioxide induces proteasome dependent TBLR1-RARα degradation to improve leukemia eradication through cell differentiation enhancement.

Authors:  Yirui Chen; Manning Li; Han Wu; Shijin Yuan; Yan Xia; Yingjian Wang; Ye Peng; Jianping Lan; Yanzhong Wang
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.478

7.  Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer.

Authors:  Tilo Wuensch; Jonas Wizenty; Janina Quint; Wolfgang Spitz; Madeleen Bosma; Olaf Becker; Andreas Adler; Wilfried Veltzke-Schlieker; Martin Stockmann; Sascha Weiss; Matthias Biebl; Johann Pratschke; Felix Aigner
Journal:  Gastroenterol Res Pract       Date:  2019-04-09       Impact factor: 2.260

8.  A novel fusion protein TBLR1-RARα acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies.

Authors:  Shouyun Li; Xue Yang; Shuang Liu; Yirui Chen; Haiyan Xing; Kejing Tang; Zheng Tian; Yingxi Xu; Qing Rao; Min Wang; Jianxiang Wang
Journal:  Cell Death Dis       Date:  2021-06-11       Impact factor: 8.469

Review 9.  Classic and Variants APLs, as Viewed from a Therapy Response.

Authors:  Marie-Claude Geoffroy; Hugues de Thé
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

10.  [Acute promyelocytic leukemia with STAT3-RARα fusion gene: a case report and literatures review].

Authors:  X X Xu; Z H Lyu; K Q Liu; Z S Meng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.